Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 608

Results For "AI"

8746 News Found

Vikas Lifecare consolidated Q1FY23 PAT at Rs. 2.59 Cr
News | July 26, 2022

Vikas Lifecare consolidated Q1FY23 PAT at Rs. 2.59 Cr

The company has reported total income of Rs. 94.30 crores during the period ended June 30, 2022.


GlaxoSmithKline Pharmaceuticals Q1FY23 consolidated PAT at Rs. 119.28 Cr
News | July 26, 2022

GlaxoSmithKline Pharmaceuticals Q1FY23 consolidated PAT at Rs. 119.28 Cr

GlaxoSmithKline Pharmaceuticals has reported total income of Rs. 772.71 crores during the period ended June 30, 2022


Urinary incontinence 2nd biggest reason for limited mobility in elderly: Survey
News | July 26, 2022

Urinary incontinence 2nd biggest reason for limited mobility in elderly: Survey

72.5% elderly feel their generation used to spend more time with their elders, 52.4% feel lonely, shows PAN Health’s Liberty in Life of Older People 2022 survey


Cadila Pharma bags ‘Rising Digital Star’ award at DigipharmaX
News | July 26, 2022

Cadila Pharma bags ‘Rising Digital Star’ award at DigipharmaX

The Award reinforces Cadila’s digital initiatives which is backed by innovation, research & development and robust frameworks.


Suven Life Sciences posts Q1FY23 consolidated loss at Rs. 16.32 Cr
News | July 26, 2022

Suven Life Sciences posts Q1FY23 consolidated loss at Rs. 16.32 Cr

Suven Life Sciences has reported total income of Rs. 3.97 crores during the period ended June 30, 2022


Sanofi India Q2 CY2022 PAT drops 49.5% to Rs. 120.4 Cr
News | July 26, 2022

Sanofi India Q2 CY2022 PAT drops 49.5% to Rs. 120.4 Cr

Sanofi India has reported total income of Rs. 715 crores during the period ended June 30, 2022.


Sun Pharma and Cosmo announce territory expansion of license and supply agreements for WINLEVI
Supply Chain | July 26, 2022

Sun Pharma and Cosmo announce territory expansion of license and supply agreements for WINLEVI

Sun Pharma will receive from Cassiopea the exclusive right to develop and commercialize WINLEVI in Japan, Australia, New Zealand, Brazil, Mexico and Russia.


Funds for R&D in drug discovery and manufacturing :PIB
Policy | July 26, 2022

Funds for R&D in drug discovery and manufacturing :PIB

An outlay of Rs. 1,500 crore has been approved for strengthening/ up-gradation of these NIPERs for the period 2021-22 to 2025-26.


Merck opens microbiology application lab in Jigani, Bengaluru
Clinical Trials | July 24, 2022

Merck opens microbiology application lab in Jigani, Bengaluru

Merck’s first microbiology application and training lab in India